BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 20304082)

  • 1. Detection and control of a nosocomial respiratory syncytial virus outbreak in a stem cell transplantation unit: the role of palivizumab.
    Kassis C; Champlin RE; Hachem RY; Hosing C; Tarrand JJ; Perego CA; Neumann JL; Raad II; Chemaly RF
    Biol Blood Marrow Transplant; 2010 Sep; 16(9):1265-71. PubMed ID: 20304082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nosocomial Respiratory Viral Infection in the Neonatal Intensive Care Unit.
    Vain NE
    Am J Perinatol; 2020 Sep; 37(S 02):S22-S25. PubMed ID: 32898879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of palivizumab to control an outbreak of syncytial respiratory virus in a neonatal intensive care unit.
    Abadesso C; Almeida HI; Virella D; Carreiro MH; Machado MC
    J Hosp Infect; 2004 Sep; 58(1):38-41. PubMed ID: 15350712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Experience with the use of palivizumab together with infection control measures to prevent respiratory syncytial virus outbreaks in neonatal intensive care units.
    Kurz H; Herbich K; Janata O; Sterniste W; Bauer K
    J Hosp Infect; 2008 Nov; 70(3):246-52. PubMed ID: 18799241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of palivizumab monoclonal antibody to control an outbreak of respiratory syncytial virus infection in a special care baby unit.
    Cox RA; Rao P; Brandon-Cox C
    J Hosp Infect; 2001 Jul; 48(3):186-92. PubMed ID: 11439005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nosocomial respiratory syncytial virus infections in the palivizumab-prophylaxis era with implications regarding high-risk infants.
    Ashkenazi-Hoffnung L; Dotan M; Livni G; Amir J; Bilavsky E
    Am J Infect Control; 2014 Sep; 42(9):991-5. PubMed ID: 25179332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of palivizumab with other infection control measures to control respiratory syncytial virus outbreaks in neonatal care units.
    Hammoud MS; Al-Taiar A; Raina A; Elsori D; Al-Qabandi S; Al-Essa M
    J Trop Pediatr; 2016 Oct; 62(5):409-14. PubMed ID: 27118823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Palivizumab prophylaxis during nosocomial outbreaks of respiratory syncytial virus in a neonatal intensive care unit: predicting effectiveness with an artificial neural network model.
    Saadah LM; Chedid FD; Sohail MR; Nazzal YM; Al Kaabi MR; Rahmani AY
    Pharmacotherapy; 2014 Mar; 34(3):251-9. PubMed ID: 23897635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of palivizumab and infection control measures to control an outbreak of respiratory syncytial virus in a neonatal intensive care unit confirmed by real-time polymerase chain reaction.
    O'Connell K; Boo TW; Keady D; Niriain U; O'Donovan D; Commane M; Faherty C; Cormican M
    J Hosp Infect; 2011 Apr; 77(4):338-42. PubMed ID: 21330007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RSV outbreak in a paediatric intensive care unit.
    Thorburn K; Kerr S; Taylor N; van Saene HK
    J Hosp Infect; 2004 Jul; 57(3):194-201. PubMed ID: 15236847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Restrictive Palivizumab Use Does Not Lead to Increased Morbidity and Mortality in Pediatric Hematopoietic Stem Cell Transplantation Patients.
    Teusink-Cross A; Davies SM; Danziger-Isakov L; El-Bietar J; Grimley MS
    Biol Blood Marrow Transplant; 2016 Oct; 22(10):1904-1906. PubMed ID: 27422147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Control of an outbreak of respiratory syncytial virus infection in immunocompromised adults.
    Jones BL; Clark S; Curran ET; McNamee S; Horne G; Thakker B; Hood J
    J Hosp Infect; 2000 Jan; 44(1):53-7. PubMed ID: 10633054
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful prevention of respiratory syncytial virus nosocomial transmission following an enhanced seasonal infection control program.
    Lavergne V; Ghannoum M; Weiss K; Roy J; Béliveau C
    Bone Marrow Transplant; 2011 Jan; 46(1):137-42. PubMed ID: 20383207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nosocomial respiratory syncytial virus infections: prevention and control in bone marrow transplant patients.
    Garcia R; Raad I; Abi-Said D; Bodey G; Champlin R; Tarrand J; Hill LA; Umphrey J; Neumann J; Englund J; Whimbey E
    Infect Control Hosp Epidemiol; 1997 Jun; 18(6):412-6. PubMed ID: 9181397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcome of the Respiratory Syncytial Virus related acute lower respiratory tract infection among hospitalized newborns: a prospective multicenter study.
    Alan S; Erdeve O; Cakir U; Akduman H; Zenciroglu A; Akcakus M; Tunc T; Gokmen Z; Ates C; Atasay B; Arsan S;
    J Matern Fetal Neonatal Med; 2016; 29(13):2186-93. PubMed ID: 26365531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage.
    Romero JR
    Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S46-54. PubMed ID: 12671452
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Respiratory syncytial virus outbreak defined by rapid screening in a neonatal intensive care unit.
    Dizdar EA; Aydemir C; Erdeve O; Sari FN; Oguz S; Uras N; Dilmen U
    J Hosp Infect; 2010 Aug; 75(4):292-4. PubMed ID: 20299133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Respiratory syncytial virus outbreak in a tertiary hospital Neonatal Intensive Care Unit].
    Moreno Parejo C; Morillo García A; Lozano Domínguez C; Carreño Ochoa C; Aznar Martín J; Conde Herrera M
    An Pediatr (Barc); 2016 Sep; 85(3):119-27. PubMed ID: 26776167
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase 1 evaluation of the respiratory syncytial virus-specific monoclonal antibody palivizumab in recipients of hematopoietic stem cell transplants.
    Boeckh M; Berrey MM; Bowden RA; Crawford SW; Balsley J; Corey L
    J Infect Dis; 2001 Aug; 184(3):350-4. PubMed ID: 11443562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Palivizumab prophylaxis against respiratory syncytial virus infection in patients younger than 2 years of age with congenital heart disease.
    Mohammed MHA; Agouba R; Obaidy IE; Alhabshan F; Abu-Sulaiman R
    Ann Saudi Med; 2021; 41(1):31-35. PubMed ID: 33550912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.